Help with Hypoglycemia

The DCCT and other studies highlight the benefit of tight glycemic control in people with type 1 and type 2 diabetes.2 The challenge continues to be achieving this tight control without increasing the incidence of hypoglycemia. By displaying the direction and rate of glucose change, CGM provides greater insight than just a glucose value at a single point in time. Real time glucose trends and alerts can help your patients respond proactively before their glucose drops too low. CGM is the tool that helps your patients achieve tight control.1

CGM helps more adults get to A1c Goals (<7%) without severe hypoglycemia1

In a recent JDRF study, more adults were able to achieve the ADA target A1c goal without incidence of severe hypoglycemia (<50mg/dL) when using CGM.1

CGM use proven to sustain hypoglycemia reduction for 12 months4

Over the 12 months of the JDRF study, CGM reduced time spent in the hypoglycemic range (<60 mg/dL) for subjects with a high A1c and those with well-controlled A1c, demonstrating that CGM can be beneficial for patients across all spectrums of glycemic control.3,4

Accuracy Where it Matters Most

A common side effect of intensive diabetes management is hypoglycemia. Hypoglycemia can not only be debilitating and have deleterious consequences but can diminish counterregulatory hormone response and induce hypoglycemia unawareness, resulting in a cycle of hypoglycemia and an increased risk of subsequent severe hypoglycemia. Even with the use of insulin pumps and long-acting insulin analogs, significant nocturnal hypoglycemia is common.7

CGM Performance in the Hypoglycemia Range12, 13

With its unique severe hypoglycemia alarm at 55mg/dL, excellent performance in the hypoglycemia range and consistent accuracy over time, the Dexcom® SEVEN® PLUS is leading the way in providing your patients reliable glucose information when it matters most.13

Not All CGMs are Created Equal - It’s All About The Technology

Dexcom’s ability to deliver accurate performance drives from our historical roots in developing long-term implantable sensor technology.

  • Sensor Geometry and Membrane Technology

    Dexcom’s round platinum electrode along with a multi-layered membrane technology results in a sensor that delivers reliable performance, accuracy in the hypoglycemia range, and contributes to minimum lag time.8

The Only CGM that Matters is the One Patients will Wear

86% of patients on the Dexcom® SEVEN® PLUS are satisfied or very satisfied with their system14

Lag Time - Take the Guesswork Out

Lag time is a reality for all sensors. SEVEN PLUS has overcome the challenge of minimizing CGM lag time. The time difference between when changes in blood glucose appear in the SEVEN PLUS CGM data, known as lag time, has been shown to be 5 minutes on average.8 With a short lag time and excellent accuracy in the hypoglycemia range13, the SEVEN PLUS can provide the alert when you cross a threshold and avoid the nuisance alerts used by other sensors to predict hypoglycemia.

Performance You Can Count On

Approved by the FDA for up to 7 days of wear, our sensors not only offer a long sensor life but have the highest percentage that last up to the limit of labeled use.12,13 This provides added performance, value and less hassle, all while providing the robust information you need to manage your patients’ diabetes.

A growing body of research is showing that CGM can provide short- and long-term clinical benefits to a wide group of patients.1,2,4,6,15-20

CGM & MDI6,26

Patients that inject insulin (MDI patients) and those that infuse insulin (CSII patients) have similar needs. Both can have problems with hypoglycemia, nocturnal hypoglycemia, and fear of hypoglycemia. CGM can detect hypoglycemia no matter how insulin is delivered. Both patients have issues with hyperglycemia, in particular post meal highs. CGM detects hyperglycemia both in patients that inject and infuse insulin, providing information that is actionable to all those who use rapid acting insulin.1,6,15-17,21,22

Yet, CGM continues to be associated for use with continuous subcutaneous insulin infusion (CSII / insulin pumps) even though patients on MDI may benefit just as significantly from its use as do those on insulin pumps. Time spent in target zone significantly improved in both groups.22-24

One Device, Two Modes, You Decide

The Dexcom® SEVEN® PLUS provides you with the simplicity of one device with the option of two modes, enabling you to choose the right mode for the right patient.

Unblinded Mode

In Unblinded Mode, your patients will see glucose values, trends and rate of change arrows as they occur in real-time, giving your patients the ability to proactively detect hypo- and hyperglycemic events. This gives you the ability to understand your patient’s self-management and decision-making skills to help coach them to improved outcomes.

Blinded Mode

In Blinded Mode, your patient will not see glucose values or trending information; no alerts and alarms activated. This will allow you to capture up to 7 days’ of your patients’ unadulterated glucose profiles for review and analysis. In the JDRF study, hypoglycemia detected in 7 days of blinded wear was predictive of subsequent hypoglycemia risk.4

Simple to Use. Simple to Learn

With almost 90% of Dexcom users trained in under an hour15, Dexcom makes training simple for both you and your patients. In fact, more than half of Dexcom users self-train on the SEVEN® PLUS system.25 This allows you to spend more time helping your patients and less time with the blocking and tackling of a new product.

  1. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes. N Engl J Med. 2008;359(14):1464-1476.
  2. U.K. Prospective Diabetes Study Group, Intensive Blood-Glucose Control with Sulphonylureas or Insulin Compared with Conventional Treatment and Risk of Complications in Patients with Type 2 Diabetes. Lancet, 1998;352:837-853.
  3. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB et al. Effectiveness of Sensor-Augmented Insulin Pump Therapy in Type 1 Diabetes. New England Journal of Medicine, June 29, 2010.
  4. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Sustained Benefits of Continuous Glucose Monitoring on HbA1c, Glucose Profiles, and Hypoglycemia in Adults with Type 1 Diabetes. Diabetes Care Published Ahead of Print, published on line August 12, 2009.
  5. Kamath A et al. Analysis of Time Lags and Other Sources of Error of the Dexcom SEVEN Continuous Glucose Monitor. Diabetes Technology and Therapeutics, Vol 11, No. 11, 2009.
  6. Garg S, Jovanovic L. Relationship of Fasting and Hourly Blood Glucose Levels to HbA1c Values: safety, accuracy and improvements in glucose profiles obtained using a 7-day continuous glucose sensor. Diabetes Care, 2006;29(12):2644-2649.
  7. Cox DJ, Gonder-Frederick L, Ritterband L, Clarke W, Kovatchev BP. Prediction of severe hypoglycemia. Diabetes Care. 2007 Jun:30(6):1370-3. Epub 2007 Mar 15.
  8. Bailey T, Zisser H, Chang A. New Features and Performance of a Next-Generation SEVEN-Day Continuous Glucose Monitoring System with Short Lag Time. Diabetes Technology & Therapeutics, 2009, Vol 11. No. 12:749-755.
  9. Weinstein RL, et al. Diabetes Care, 2007;30(5):1125-3110.
  10. Medtronic only reports overall Mean ARD data.
  11. Dexcom SEVEN PLUS Summary of Safety and Effectiveness Data (SSED), 2008.
  12. Based on manufacturer user’s guides. FreeStyle Navigator, 2008. Medtronic Paradigm REAL-Time Revel, 2009.
  13. Based on manufacturer user’s guides. Dexcom SEVEN PLUS, 2008.
  14. Dexcom Customer Satisfaction Evaluation, April 2010.
  15. Deiss D, Bolinder J, Riveline JP, et al. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care. 2006; 29(12):2730-2732.
  16. Bailey TS, Zisser HC, Garg SK. Reduction in hemoglobin A1c with real-time continuous glucose monitoring: results from a 12-week observational study. Diabetes Technol Ther. 2007; 9(3):203-210.
  17. Garg SK, Kelly WC, Voelmle MK, et al. Continuous home monitoring of glucose: improved glycemic control with real-life use of continuous glucose sensors in adult subjects with type 1 diabetes. Diabetes Care. 2007;30(12):3023-3025.
  18. Brownlee M, et al. Glycemic Variability: A Hemoglobin A1c-Independent Risk Factor for Diabetic Complications. JAMA. 2006;295(14):1707-1708.
  19. American Diabetes Association. Standards of Medical Care in Diabetes – 2009. Diabetes Care;2009 32(Suppl 1) S13-61.
  20. JDRF Continuous Glucose Monitoring Study Group. The Effect of Continuous Glucose Monitoring in Well-Controlled Type 1 Diabetes. Diabetes Care;2009;32(5):1378-1383.
  21. Garg SK, Smith J, Beatson C, Lopez-Baca B, Voelmle M, Gottlieb PA. Comparison of accuracy and safety of the SEVEN and the Navigator continuous glucose monitoring systems. Diabetes Technol Ther. 2009; 11(2):65-72.
  22. Rodbard D, Jovanovic L, Garg SK. Responses to continuous glucose monitoring in subjects with type 1 diabetes using continuous subcutaneous insulin infusion or multiple daily injections. Diab Tech Ther. 2009;11:757-763.
  23. Garg, S. Role of Continuous Glucose Monitoring in Patients with Diabetes using Multiple Daily Insulin Injections. Infusystems USA. Vol.6 No.2, 2009:10-12.
  24. Garg, S. Best Practices in: Continuous Glucose Monitoring and Multiple Daily Injections. Clinical Endocrinology News. March 2010.
  25. Training metrics gathered from January to March 2011 with the launch of the new SEVEN PLUS training materials and training methods.
  26. 21-day study, n = 86 (50% CSII, 50% MDI) to evaluate efficacy of the 7-day system.